Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib

International Journal of Urology

Volumn 18, Issue 6, 2011, Pages 422-430

  Zhang, Hai Liang ^a   Zhu, Yao ^a   Wang, Chao Fu ^a   Yao, Xu Dong ^a   Zhang, Shi Lin ^a   Dai, Bo ^a   Shen, Yi Jun ^a   Zhu, Yi Ping ^a   Shi, Guo Hai ^a   Ye, Ding Wei ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Erythrocyte sedimentation rate; Metastatic renal cell carcinoma; Prognostic factor; Sorafenib

Indexed keywords

ALBUMIN; ALPHA INTERFERON; CALCIUM; INTERLEUKIN 2; LACTATE DEHYDROGENASE; SORAFENIB; SUNITINIB;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHINESE; CHINESE MEDICINE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; KINETICS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; PYRIDINES;

EID: 79956281131     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02761.x     Document Type: Article

References (30)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 2005; 353: 2477-90.
2. Motzer RJ, Escudier B, Oudard S etal. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
3. Motzer RJ, Hutson TE, Tomczak P etal. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 115-24.
4. Hudes G, Carducci M, Tomczak P etal. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 2271-81.
5. Escudier B, Pluzanska A, Koralewski P etal. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11.
6. Escudier B, Eisen T, Stadler WM etal. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 125-34.
7. Zhang H, Dong B, Lu JJ etal. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 2009; 9: 249-56.
8. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J. Clin. Oncol. 2007; 37: 755-62.
9. Negrier S, Escudier B, Gomez F etal. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann. Oncol. 2002; 13: 1460-8.
10. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999; 17: 2530-40.
11. Motzer RJ, Bukowski RM, Figlin RA etal. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113: 1552-8.
12. Montero AJ, Diaz-Montero CM, Millikan RE etal. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival. Ann. Oncol. 2009; 20: 1682-7.
13. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin. Cancer Res. 2010; 16: 4853-63.
14. Kawai Y, Matsuyama H, Korenaga Y etal. Preoperative erythrocyte sedimentation rate is an independent prognostic factor in Japanese patients with localized clear cell renal cell carcinoma. Urol. Int. 2009; 83: 306-10.
15. Sengupta S, Lohse CM, Cheville JC etal. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 2006; 106: 304-12.
16. Iversen OH, Roger M, Solberg HE, Wetteland P. Rising erythrocyte sedimentation rate during several years before diagnosis can be a predictive factor in 70% of renal cell carcinoma patients. The benefit of knowing subject-based reference values. J. Intern. Med. 1996; 240: 133-41.
17. Donmez T, Kale M, Ozyurek Y, Atalay H. Erythrocyte sedimentation rates in patients with renal cell carcinoma. Eur. Urol. 1992; 21 (Suppl 1): 51-2.
18. Hannisdal E, Bostad L, Grottum KA, Langmark F. Erythrocyte sedimentation rate as a prognostic factor in renal cell carcinoma. Eur. J. Surg. Oncol. 1989; 15: 333-6.
19. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur. Urol. 2006; 49: 798-805.
20. Plebani M, Piva E. Erythrocyte sedimentation rate: use of fresh blood for quality control. Am. J. Clin. Pathol. 2002; 117: 621-6.
21. Sene AP, Hunt L, McMahon RF, Carroll RN. Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br. J. Urol. 1992; 70: 125-34.
22. Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am. Fam. Physician 1999; 60: 1443-50.
23. Peyman MA. The effect of malignant disease on the erythrocyte sedimentation rate. Br. J. Cancer 1962; 16: 56-71.
24. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
25. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
26. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
27. Gobbi PG, Ghirardelli ML, Solcia M etal. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J. Clin. Oncol. 2001; 19: 1388-94.
28. Zaman K, Driscoll R, Hahn D etal. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int. J. Cancer 2006; 118: 755-64.
29. Balakrishnan C, Mangat G, Joshi VR. Anaemia and raised erythrocyte sedimentation rate. J. Assoc. Physicians India 1995; 43: 303-7.
30. Terry R. Erythrocyte sedimentation in anaemia. Br. Med. J. 1950; 2: 1296-9.